I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease
There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care. The primary objective of I-CARE was to assess prospectively safety concerns in IBD, with specific focus on the risk of cancer/lymphoma and serious...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2023
|
| Sorozat: | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
21 No. 3 |
| Tárgyszavak: | |
| doi: | 10.1016/j.cgh.2022.09.018 |
| mtmt: | 33127876 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/25281 |
| LEADER | 03162nab a2200397 i 4500 | ||
|---|---|---|---|
| 001 | publ25281 | ||
| 005 | 20230302113338.0 | ||
| 008 | 221006s2023 hu o 0|| Angol d | ||
| 022 | |a 1542-3565 | ||
| 024 | 7 | |a 10.1016/j.cgh.2022.09.018 |2 doi | |
| 024 | 7 | |a 33127876 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Angol | ||
| 100 | 2 | |a Peyrin-Biroulet Laurent | |
| 245 | 1 | 0 | |a I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease |h [elektronikus dokumentum] / |c Peyrin-Biroulet Laurent |
| 260 | |c 2023 | ||
| 300 | |a 771-788 | ||
| 490 | 0 | |a CLINICAL GASTROENTEROLOGY AND HEPATOLOGY |v 21 No. 3 | |
| 520 | 3 | |a There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care. The primary objective of I-CARE was to assess prospectively safety concerns in IBD, with specific focus on the risk of cancer/lymphoma and serious infections in patients treated with for anti-tumor necrosis factor and other biologics monotherapy as well as in combination with immunomodulators.I-CARE was designed as a European prospective longitudinal observational multicenter cohort study, to include patients with a diagnosis of Crohn's disease, ulcerative colitis or IBD unclassified established at least 3 months prior to enrollment.A total of 10,206 patients were enrolled between March 2016 and April 2019, including 6,169 (60.4%) patients with Crohn's disease, 3,853 (37.8%) with ulcerative colitis, and 184 (1.8%) with a diagnosis of IBD unclassified. Thirty-two percent of patients were receiving AZA/thiopurines, 4.6% 6-mercaptopurine, and 3.2% methotrexate at study entry. At inclusion, 47.3% of patients were treated with an anti-tumor necrosis factor agent, 8.8% with vedolizumab, and 3.4% with ustekinumab. Roughly one quarter of patients (26.8%) underwent prior IBD related surgery. Sixty-six % of patients had been previously treated with systemic steroids. Three percent of patients had a medical history of cancer prior to inclusion, and 1.1% had a history of colonic, esophageal or uterine cervix high-grade dysplasia.I-CARE is an ongoing investigator-initiated observational European prospective cohort study that will provide unique information on the long-term benefits and risks of biological therapies in IBD patients. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 1 | |a Rahier Jean-François |e aut |
| 700 | 0 | 1 | |a Kirchgesner Julien |e aut |
| 700 | 0 | 1 | |a Abitbol Vered |e aut |
| 700 | 0 | 1 | |a Sebastian Shaji |e aut |
| 700 | 0 | 1 | |a Armuzzi Alessandro |e aut |
| 700 | 0 | 1 | |a Karmiris Konstantinos |e aut |
| 700 | 0 | 1 | |a Gisbert Javier P. |e aut |
| 700 | 0 | 1 | |a Bossuyt Peter |e aut |
| 700 | 0 | 1 | |a Helwig Ulf |e aut |
| 700 | 0 | 1 | |a Burisch Johan |e aut |
| 700 | 0 | 1 | |a Yanai Henit |e aut |
| 700 | 0 | 2 | |a Glen A. Doherty |e aut |
| 700 | 0 | 2 | |a Molnár Tamás |e aut |
| 700 | 0 | 2 | |a Kollaborációs Szervezet: I-CARE Collaborator Group |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/25281/1/Peyrin2022.pdf |z Dokumentum-elérés |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/25281/7/33127876_megjelent.pdf |z Dokumentum-elérés |